



Attorney Docket No. Le A 33 878

ORIGINAL

1626
S
P.G.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Alonso-Alija, et al.

Group No.:1626

Application No.: 10/088,060

Examiner: Saeed, Kamal A.


Filed: 06/02/2002

For: Novel Derivatives of Dicarboxylic Acid Having Pharmaceutical Properties

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: June 18, 2004


Eugenia Boshnack

Eugenia Boshnack

Assistant Commissioner for Patents
Washington, D.C. 22313

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING DATE OF EITHER A FINAL ACTION
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

TIME OF TRANSMITTAL OF ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement transmitted herewith is being filed **after** three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but **before** the mailing date of either
 - (1) a final action under section 1.113 or
 - (2) a notice of allowance under section 1.311whichever occurs first.

FEE

2. Accompanying this transmittal is the fee for submission of an information disclosure statement under § 1.97(c). (\$180.00)

06/24/2004 GWORDOF1 00000056 133372 10088060

01 FC:1806 180.00 DA



ORIGINAL

Attorney Docket No. Le A 33 878

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$ 180.00

METHOD OF PAYMENT OF FEE

4. Please charge Account No. 13-3372 in the amount of \$ 180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

William F. Gray
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No. 31,018

Telephone: (203) 812-2712

Date: 17 June '04

INFORMATION DISCLOSURE CITATION

Applicant(s)

Alonso-Alija, et al.

JUN 21 2004
U.S. PATENT DOCUMENTS

DOCUMENT NO.

DATE
(MM/DD/YY)

NAME

CLASS

SUB-
CLASSFILING DATE
IF
APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NO.

DATE
(DD/MM/YY)

COUNTRY

PRIMARY
CLASSSUB-
CLASS

TRANSLATION

YES

NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	R1	Stasch, et al., "NO- and Haem-independent Activation of Soluble Guanylyl Cyclase: Molecular Basis and Cardiovascular Implications of a New Pharmacological Principle." <i>Brit. J. of Pharma.</i> , <u>136</u> , 773-783, (2002).
	R2	Weber, et al., "The Effect of Peroxynitrate on the Catalytic Activity of Soluble Guanylyl Cyclase," <i>Free Rad. Bio. & Med.</i> , <u>31</u> , 1360-1367, (2001).
	R3	Pryor, et al., "The Chemistry of Peroxynitrate: A product from the Reaction of Nitric Oxide with Superoxide", <i>Am. J. Physiol.</i> , <u>268</u> , L699-L722,(1995).
	R4	Harrison, M.D. et al., "Endothelial Function and Oxidant Stress", <i>Clin. Cardiol.</i> , <u>20</u> , II-11-17, (1997).
	R5	Stasch, et al., "Pharmacological Actions of a Novel NO-Independent Guanylyl Cyclase Stimulator, Bay 41-8543: <i>in vitro</i> Studies." <i>Brit. J. of Pharma.</i> <u>135</u> , 333-343, (2002).
	R6	Schrammel, et al., "Characterization of 1 <i>H</i> -[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one as a Heme-Site Inhibitor of Nitric Oxide-Sensitive Guanylyl Cyclase." <i>Mol. Pharmacology</i> , <u>50</u> , 1-5, (1996).
	R7	Schmidt, et al., "Mechanisms of Nitric Oxide Independent Activation of Soluble Guanylyl Cyclase," <i>Eur. J. Pharmacol.</i> <u>468</u> , 167-174, (2003).
	R8	Garthwaite, et al., "Potent and Selective Inhibition of Nitric Oxide-Sensitive Guanylyl Cyclase by 1 <i>H</i> -[1,2,4]Oxadiazolo[4,3-a] quinoxalin-1-one", <i>Mol. Pharma.</i> , <u>48</u> 184-188, (1995).
	R9	Schmidt, et al., "Identification of Residues Crucially Involved in the Binding of the Heme Moiety of Soluble Guanylate Cyclase", <i>J. Biol. Chem.</i> (in press, 2003).
	R10	Mulsch et al., <i>Circulation</i> , <u>102</u> , II-351 (2000).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.